Bionomics Inc.

Genentech, Inc.

Walter and Eliza Hall Institute of Medical Research

Abbott Laboratories Corporation

Abbvie Inc.

Chinh Thien Bui

Jonathan Bayldon Baell

Brad E Sleebs

Bernard Luke Flynn

Nurul Quazi

Ian Phillip Street

Andrew J Souers

Keith G Watson

John A Flygare

Steven Elmore

Chudi Obioma Ndubaku

Wayne J Fairbrother

Andrew M Petros

Danette Dudley

Guillaume Laurent Lessene

Brian John Smith

Peter Colman

Peter Edward Czabotar

George Nikolakopoulos

Carl Steven Rye

Ian Philip Street

Keith Geoffrey Watson

Steven W Elmore

Brad Edmund Sleebs

Danette A Dudley

Xilu Wang

Le Wang

Zhi-Fu Tao

Lisa A Hasvold

Kurt Deshayes

Brad Sleebs

The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.

Anxiolytic compounds

The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

Growing community of inventors

North Balwyn, Australia

Chinh Thien Bui